MedTrace Logo

Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition

NCT00774475 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 442

Last updated 2008-10-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy (reduction of major ischemic events at 6 and 12 months of follow-up) of a tailored clopidogrel therapy in patients with UA/NSTEMI undergoing PCI with stent implantation and wiht a documented residual platelet reactivity assessed by a point of care system (VerifyNow P2Y12).

Conditions

  • Unstable Angina
  • NSTEMI

Interventions

DRUG

comparison of different dosage of clopidogrel

clopidogrel 75 mg/day versus clopidogrel 150 mg/day

DRUG

doubled therapy

clopidogrel 150 mg/day

Sponsors & Collaborators

  • Tuscany Region

    collaborator UNKNOWN

  • University of Florence

    lead OTHER

Principal Investigators

  • Gian Franco Gensini, MD · University of Florence

  • Gianni Maria Santoro, MD · ASL 10 Florence, Italy

  • Niccolò Marchionni, MD · University of Florence

  • David Antoniucci, MD · Azienda Ospedaliero-Universitaria Careggi

  • Alfredo Zuppiroli, MD · ASL 10 Florence Italy

  • Maria Cristina Landini, MD · ASL 10 Florence Italy

  • Rosanna Abbate, MD · University of Florence

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-11-30
Completion
2011-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00774475 on ClinicalTrials.gov